Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial
W. Joseph Herring, Paulette Ceesay, Ellen Snyder, et al.
Alzheimer s & Dementia (2020) Vol. 16, Iss. 3, pp. 541-551
Open Access | Times Cited: 138

Showing 1-25 of 138 citing articles:

Alzheimer's disease drug development pipeline: 2020
Jeffrey L. Cummings, Garam Lee, Aaron Ritter, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 498
Alzheimer's disease drug development pipeline: 2021
Jeffrey L. Cummings, Garam Lee, Kate Zhong, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 414
Alzheimer's disease drug development pipeline: 2023
Jeffrey L. Cummings, Yadi Zhou, Garam Lee, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2023) Vol. 9, Iss. 2
Open Access | Times Cited: 321
New approaches to symptomatic treatments for Alzheimer’s disease
Jeffrey L. Cummings
Molecular Neurodegeneration (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 161
The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents
Christoph U. Correll, Marco Solmi, Samuele Cortese, et al.
World Psychiatry (2023) Vol. 22, Iss. 1, pp. 48-74
Open Access | Times Cited: 82
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS
Brendan P. Lucey, Haiyan Liu, Cristina D. Toedebusch, et al.
Annals of Neurology (2023) Vol. 94, Iss. 1, pp. 27-40
Open Access | Times Cited: 44
Treatment of Alzheimer Disease
David Geldmacher
CONTINUUM Lifelong Learning in Neurology (2024) Vol. 30, Iss. 6, pp. 1823-1844
Closed Access | Times Cited: 19
Associations of sleep disorders with all-cause MCI/dementia and different types of dementia – clinical evidence, potential pathomechanisms and treatment options: A narrative review
Geert Mayer, Helmut Frohnhofen, Martha Jokisch, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 18
Pharmacological and non‐pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic review
Jonathan Blackman, Marta Swirski, James Clynes, et al.
Journal of Sleep Research (2020) Vol. 30, Iss. 4
Open Access | Times Cited: 87
Pharmacotherapies for sleep disturbances in dementia
Jenny McCleery, Ann L. Sharpley
Cochrane library (2020) Vol. 2020, Iss. 11
Open Access | Times Cited: 83
New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease
Feng Zhang, Rujia Zhong, Cheng Cheng, et al.
Acta Pharmacologica Sinica (2020) Vol. 42, Iss. 9, pp. 1382-1389
Open Access | Times Cited: 72
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis
Tao Xue, Xin Wu, Shujun Chen, et al.
Sleep Medicine Reviews (2021) Vol. 61, pp. 101573-101573
Closed Access | Times Cited: 68
Sensory-Evoked 40-Hz Gamma Oscillation Improves Sleep and Daily Living Activities in Alzheimer’s Disease Patients
Aylin Cimenser, Evan Hempel, Taylor Travers, et al.
Frontiers in Systems Neuroscience (2021) Vol. 15
Open Access | Times Cited: 67
The orexin story, sleep and sleep disturbances
Fabio Pizza, Lucie Barateau, Yves Dauvilliers, et al.
Journal of Sleep Research (2022) Vol. 31, Iss. 4
Closed Access | Times Cited: 48
A Growing Link between Circadian Rhythms, Type 2 Diabetes Mellitus and Alzheimer’s Disease
Xuemin Peng, Rongping Fan, Lei Xie, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 1, pp. 504-504
Open Access | Times Cited: 41
The orexin story and orexin receptor antagonists for the treatment of insomnia
Clemens Muehlan, Catherine Roch, Cédric Vaillant, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 6
Open Access | Times Cited: 39
Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART
Alexander J. Ehrenberg, Michael A. Kelberman, Kathy Liu, et al.
Alzheimer s & Dementia (2023) Vol. 19, Iss. 5, pp. 2182-2196
Open Access | Times Cited: 34
Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs
Ashvin Varadharajan, Aarjith Damian Davis, Aishwarya Ghosh, et al.
Journal of Neurosciences in Rural Practice (2023) Vol. 14, pp. 566-573
Open Access | Times Cited: 32
Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer’s disease
Christopher D. Morrone, Radha Raghuraman, S. Abid Hussaini, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 27
Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases
Britney N. Lizama, Jennifer Kahle, Susan M. Catalano, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6251-6251
Open Access | Times Cited: 25
A 2023 Update on Managing Insomnia in Primary Care
Russell Rosenberg, Ruth M. Benca, Paul P. Doghramji, et al.
The Primary Care Companion For CNS Disorders (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 24
Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations
Maria P. Mogavero, Alessandro Silvani, Giuseppe Lanza, et al.
Nature and Science of Sleep (2023) Vol. Volume 15, pp. 17-38
Open Access | Times Cited: 23
Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies
Russell Rosenberg, Leslie Citrome, Christopher L. Drake
Neuropsychiatric Disease and Treatment (2021) Vol. Volume 17, pp. 2549-2566
Open Access | Times Cited: 47
Page 1 - Next Page

Scroll to top